you can not get a med into clinical trials without first doing Tox. This is true for virtually every country.
They can not complete Tox because they can not manufacture verifiably consistent batches. Not at 200g not at 1g. Scaling up is just half of the hurdle (and that has not been achieved), it is the ability to replicate and verify that is the other half of the equation. Neither have been solved.
The "results" from Moffat will be another chance to stall and delay, while creating the appearance of progress. Manufacturing (as has been pointed out for years now) is the problem...amongst many.
News 
Market Data 
Discover 
